Articles dans des revues avec comité de lecture (76)
  1. 1. Serra, M., Rediti, M., Collet, L., Lifrange, F., Venet, D., Occelli, N., Papagiannis, A., Vincent, D., Rouas, G., Larsimont, D., Vikkula, M., Duhoux, F. P., Rothé, F., & Sotiriou, C. (2026). Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 123(6), e2517567123. doi:10.1073/pnas.2517567123
  2. 2. Stanciu, M.-A., Agostinetto, E., Papagiannis, A., Pipinikas, C. P., Chevalier, A., Campbell, N., Brandão, M., Ameye, L., Paesmans, M., Besse, T., Rothé, F., Buisseret, L., Taylor, D., Neven, P., Sotiriou, C., Duhoux, F. P., Vuylsteke, P., & Ignatiadis, M. (2025). Personalized ctDNA detection and genomic profiling in the NeoRHEA Study. NPJ breast cancer, 11(1), 137. doi:10.1038/s41523-025-00852-6
  3. 3. Manley, M., Nader-Marta, G., Ozturk, A. A., Kassas, M., Rothé, F., Taraji, L., Sotiriou, C., Wimana, Z., Salgado, R., Flamenne, P., & Gebhart, G. (2025). PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial. European journal of nuclear medicine and molecular imaging. doi:10.1007/s00259-025-07667-4
  4. 4. Papagiannis, A., Majjaj, S., Duhoux, F. P., Agostinetto, E., Stanciu, M.-A., Vanhulst, T., Buisseret, L., Larsimont, D., Veys, I., Paesmans, M., Hammer, T. B., Awada, A., Ameye, L., Rothé, F., Madriles, F., Cash, T. T., Salgado, R., Willard-Gallo, K., Sotiriou, C., Vuylsteke, P., Neven, P., & Ignatiadis, M. (2025). Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study. Nature communications. doi:10.1038/s41467-025-66590-2
  5. 5. Joaquin Garcia, A., Semba, T., Rediti, M., McGrail, D. J., Xie, X., Wang, X., Rampa, D. R., Venet, D., Buisseret, L., Majjaj, S., Kammler, R., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Rothé, F., Sotiriou, C., & Ueno, N. T. (2025). Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00. iScience, 28(8), 112964. doi:10.1016/j.isci.2025.112964
  6. 6. Collet, L., Noël, J.-C., Catteau, X., Ardin, M., Berthet, J., Ghamry-Barrin, S., Treilleux, I., Bengrine Lefevre, L., Martinez, M., Rothé, F., Sotiriou, C., Caux, C., Dubois, B., Ray-Coquard, I., & Le Saux, O. (2025). Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial. ESMO Open, 10(6), 105104. doi:10.1016/j.esmoop.2025.105104
  7. 7. Collet, L., Ardin, M., Venet, D., Berthet, J., Ghamry-Barrin, S., Treilleux, I., Noel, J.-C., Leheurteur, M., Meunier, J., Bengrine Lefevre, L., Martinez, M., Priou, F., Selle, F., Just, P. A., Bataillon, G., Rothé, F., Sotiriou, C., Caux, C., Dubois, B., Ray-Coquard, I., & Le Saux, O. (2025). Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial. Clinical cancer research. doi:10.1158/1078-0432.CCR-24-2712
  8. 8. Blanc, J., Carnot, A., Barthélémy, P., Casert, V., Sautois, B., Van den Brande, J., Vanhaudenarde, V., Staudacher, L., Seront, E., Debien, V., Ameye, L., Kotecki, N., Rothé, F., Rorive, S., Fantoni, J. C., Tricard, T., Roumeguère, T., Awada, A., & Martinez Chanza, N. (2025). Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial. Journal for ImmunoTherapy of Cancer, 13(5). doi:10.1136/jitc-2025-012045
  9. 9. Rediti, M., Fimereli, D., Mileva, M., Wimana, Z., Venet, D., Flamen, P., Guiot, T., de Vries, E. E., Schröder, C. P., Menke-van der Houven van Oordt, W. C., Maetens, M. M., Majjaj, S., Larsimont, D., Rothé, F., Sotiriou, C., & Gebhart, G. (2025). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical cancer research, 31(1), 110-121. doi:10.1158/1078-0432.CCR-24-1007
  10. 10. Rediti, M., Venet, D., Joaquin Garcia, A., Maetens, M. M., Vincent, D., Majjaj, S., El-abed, S., Di Cosimo, S., Ueno, T., Izquierdo, M., Piccart-Gebhart, M., Pusztai, L., Loi, S., Salgado, R., Viale, G., Rothé, F., & Sotiriou, C. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature communications, 15(1), 10402. doi:10.1038/s41467-024-54621-3
  11. 11. Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Dupont, F., Rouas, G., Garcia, A. J., Craciun, L., Buisseret, L., Ignatiadis, M., Carausu, M., Bhalla, N., Masarapu, Y., Villacampa, E. G., Franzén, L., Saarenpää, S., Kvastad, L., Thrane, K., Lundeberg, J., Rothé, F., & Sotiriou, C. (2024). Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nature communications, 15(1), 10232. doi:10.1038/s41467-024-54145-w
  12. 12. Buisseret, L., Bareche, Y., Venet, D., Girard, E., Gombos, A., Emonts, P., Majjaj, S., Rouas, G., Serra, M., Debien, V., Agostinetto, E., Garaud, S., Willard-Gallo, K., Larsimont, D., Stagg, J., Rothé, F., & Sotiriou, C. (2024). The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO Open, 9(5), 102964. doi:10.1016/j.esmoop.2024.102964
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 Suivant >>